GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co in a research note issued on Thursday.

A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. ValuEngine downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, Morgan Stanley downgraded shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $46.00.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.27% during trading on Thursday, reaching $40.24. The company’s stock had a trading volume of 3,006,781 shares. The firm’s 50-day moving average is $39.80 and its 200-day moving average is $41.77. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54. The stock has a market cap of $98.35 billion, a P/E ratio of 39.76 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts forecast that GlaxoSmithKline PLC will post $2.87 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/16/glaxosmithkline-plc-gsk-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

A number of hedge funds have recently added to or reduced their stakes in GSK. Russell Investments Group Ltd. acquired a new position in GlaxoSmithKline PLC in the first quarter valued at $578,000. AMG National Trust Bank lifted its holdings in GlaxoSmithKline PLC by 12.5% in the first quarter. AMG National Trust Bank now owns 76,629 shares of the pharmaceutical company’s stock valued at $3,231,000 after buying an additional 8,533 shares during the period. Capital Fund Management S.A. acquired a new position in GlaxoSmithKline PLC in the first quarter valued at $588,000. TIAA CREF Trust Co. FSB MO lifted its holdings in GlaxoSmithKline PLC by 5.1% in the first quarter. TIAA CREF Trust Co. FSB MO now owns 35,222 shares of the pharmaceutical company’s stock valued at $1,485,000 after buying an additional 1,706 shares during the period. Finally, HPM Partners LLC acquired a new position in GlaxoSmithKline PLC in the first quarter valued at $516,000. Institutional investors and hedge funds own 9.29% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.